VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
NXTC
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
NXTCNextCure, Inc.
$6.88$25M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
NXTC logo

NextCure, Inc.

NXTC
NASDAQ · Oncology Biotech
$6.88
At close - Nov 18, 4:00 PM EST - USD
Market Cap$25M
P/E-0.9x
52W High$15.74
Volume17.25K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Persistent Clinical Burn Threatens Future Capital Solvency

NextCure faces a precarious outlook as it continues to operate without revenue, leading to a rapid erosion of its asset base from $128.0 million in 2023Q4 to $38.0 million in 2026Q1.

GrowthContracting
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

NXTC price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

3/12 Beats

EPS beat 3 of last 12 quarters

02

Valuation risk

-103% Peers

P/E is 103% below peer median

03

Market leadership

RS 38 · Lag

Laggard (Underperforming 62% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 10

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
NXTC-48.16%
S&P 500 (^GSPC)+6.88%
1-Year Return
NXTC-31.15%
S&P 500 (^GSPC)+10.62%
3-Year Return
NXTC-53.73%
S&P 500 (^GSPC)+67.02%
5-Year Return
NXTC-90.24%
S&P 500 (^GSPC)+59.72%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
-
Net income FY25
-$56M-0.3% YoY
Free cash flow FY25
-$50M-20.2% YoY
Operating margin FY25
-
ROIC (FY25)-149.5%
Avg ROIC 5Y-60.2%
ROE (TTM)-206.6%
Piotroski Score1 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate3/12 (25%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 10, 2026
-$1.29-43.3%
vs -$0.90
—
vs —
Q3 2026
Aug 6, 2026
-$2.80-43.6%
vs -$1.95
—
vs —
Q2 2026
May 7, 2026
-$1.87-3.3%
vs -$1.81
—
vs —
Q2 2026
Mar 5, 2026
-$0.81+64.2%
vs -$2.26
—
vs —
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

2 Stories
GlobeNewsWire·Nov 10, 2026
NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results

BALTIMORE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), today provided a business update and reported financial results for the third quarter ended September 30, 2026.

Defense World·Sep 9, 2026
NextCure (NASDAQ:NXTC) Stock Price Up 7.7% – Time to Buy?

NextCure, Inc. (NASDAQ: NXTC - Get Free Report)'s stock price was up 7.7% during trading on Tuesday. The company traded as high as $8.64 and last traded at $8.42. 95,035 shares were traded during mid-day trading, a decline of 36% from the average daily volume of 147,812 shares. The stock had previously closed at $7.82.

Filtered for NextCure, Inc.More Headlines
04

Compare before deciding

Benchmark NXTC against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for NextCure, Inc. (NXTC)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
NXTC logoNXTCNextCure, Inc.Current
$6.89$24.87M-0.89——-206.63%—
FATE logoFATEFate Therapeutics, Inc.
$1.05$122.39M-1.04-51.24%-2619.64%-73.92%—
RCUS logoRCUSArcus Biosciences, Inc.
$15.76$1.98B-4.51-4.26%-445%-90.04%—
AGEN logoAGENAgenus Inc.
$6.40$266.51M18.9710.37%20.98%——
IMVT logoIMVTImmunovant, Inc.
$33.17$6.85B-13.47—-7173.52%-63.01%—
TGTX logoTGTXTG Therapeutics, Inc.
$66.12$10.12B97.2187.32%11.81%17.62%—

Compare NXTC vs Peers

NextCure, Inc. (NXTC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs FATE

Most directly comparable listed peer for NXTC.

Scale Benchmark

vs MRK

Larger-name benchmark to compare NXTC against a more recognizable public peer.

Peer Set

Compare Top 5

vs FATE, RCUS, AGEN, IMVT

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

NXTC SEC Filings & Documents

NextCure, Inc. (NXTC) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 10, 2026·SEC

Material company update

Oct 30, 2026·SEC

Material company update

Aug 6, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 5, 2026·SEC

FY 2025

Mar 6, 2025·SEC

FY 2024

Mar 21, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 10, 2026·SEC

FY 2026

Aug 6, 2026·SEC

FY 2026

May 7, 2026·SEC

Get notified when NXTC posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

NXTC Frequently Asked Questions

NextCure, Inc. (NXTC) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
Is NXTC profitable?

No. NextCure, Inc. (NXTC) reported a net loss of $41.0M over the trailing twelve months.

Dividend & Returns
What is NXTC's return on equity?

NextCure, Inc. (NXTC) had a return on equity (ROE) of -206.6% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is NextCure, Inc.'s free cash flow?

NextCure, Inc. (NXTC) had negative free cash flow of $42.8M over the trailing twelve months.

What if you invested $1,000 in NXTC back in 2017?

Total return calculator · dividends reinvested · 9+ years of data

See returns →